Therapeutic Asset Ratings
6,308 results matching 1 filter
91,564 assets · 7,904 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Gsbr-1290
Obesity Disorder
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
P1/2
CCC
(48)
GSK-2636771
Skin Cancer
M.D. Anderson Cancer Center
P1/2
CCC
(48)
gsk4418959
Colorectal Neoplasm
GlaxoSmithKline
P1/2
CCC
(48)
gsk5458514
Prostate Cancer
GlaxoSmithKline
P1/2
CCC
(48)
gsk5460025
Colorectal Neoplasm
GlaxoSmithKline
P1/2
CCC
(48)
gsk5471713
Prostate Cancer
GlaxoSmithKline
P1/2
CCC
(48)
Guadecitabine
Kidney Cancer
Ajjai Alva, MD
P1/2
CCC
(48)
Guadecitabine
Acute Myeloid Leukemia With Multilineage Dysplasia
University of Southern California
P1/2
CCC
(48)
gw5282
T-Cell Non-Hodgkin Lymphoma
Dizal Pharmaceuticals
P1/2
CCC
(48)
h1299 cell lysates
Carcinoma
National Cancer Institute (NCI)
P1/2
CCC
(48)
Hbi 0201-Eso Tcrt
Bladder Transitional Cell Carcinoma
Hadassah Medical Organization
P1/2
CCC
(48)
Hbi 0201-Eso Tcrt
Neuroblastoma
Hadassah Medical Organization
P1/2
CCC
(48)
Hbi 0201-Eso Tcrt
Soft Tissue Sarcoma
Hadassah Medical Organization
P1/2
CCC
(48)
Hbi 0201-Eso Tcrt
Synovial Sarcoma
Hadassah Medical Organization
P1/2
CCC
(48)
H-gamma1 heavy chain Homo sapiens (1-447) [VH (Homo sapiens IGHV4-59*01 (99.0%) -(IGHD) -IGHJ3*02 (93.3%) T125>I (114), CDR-IMGT [8.7.11] (26-33.51-57.96-106)) (1-117) -Homo sapiens IGHG1*01, G1m17,1 CH1 K120, CH3 D12, L14, 9-G1v21 CH2 Y15.1, T16, E18 (CH1 K120 (214) (118-215), hinge 1-15 (216-230), CH2 M15.1>Y (252), S16>T (254), T18>E (256) (231-340), CH3 D12 (356), L14 (358) (341-445), CHS (446-447)) (118-447)], (220-214')-disulfide with L-kappa light chain Homo sapiens (1'-214') [V-KAPPA (Homo sapiens IGKV3-11*01 (96.8%) -IGKJ4*01 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (CKAPPA A45.1 (153'), V101 (191')) (108'-214')]; dimer (226-226'':229-229'')-bisdisulfide, produced in a cell line derived from Chinese hamster ovary (CHO) cells, glycoform alfa
Hepatocellular Carcinoma
Kineta Inc.
P1/2
CCC
(48)
H-gamma1 heavy chain Homo sapiens (1-447) [VH (Homo sapiens IGHV4-59*01 (99.0%) -(IGHD) -IGHJ3*02 (93.3%) T125>I (114), CDR-IMGT [8.7.11] (26-33.51-57.96-106)) (1-117) -Homo sapiens IGHG1*01, G1m17,1 CH1 K120, CH3 D12, L14, 9-G1v21 CH2 Y15.1, T16, E18 (CH1 K120 (214) (118-215), hinge 1-15 (216-230), CH2 M15.1>Y (252), S16>T (254), T18>E (256) (231-340), CH3 D12 (356), L14 (358) (341-445), CHS (446-447)) (118-447)], (220-214')-disulfide with L-kappa light chain Homo sapiens (1'-214') [V-KAPPA (Homo sapiens IGKV3-11*01 (96.8%) -IGKJ4*01 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (CKAPPA A45.1 (153'), V101 (191')) (108'-214')]; dimer (226-226'':229-229'')-bisdisulfide, produced in a cell line derived from Chinese hamster ovary (CHO) cells, glycoform alfa
Thyroid Cancer
Kineta Inc.
P1/2
CCC
(48)
High-Dose Can103
Gaucher Disease Type III
CANbridge (Suzhou) Bio-pharma Co., Ltd.
P1/2
CCC
(48)
High Dose Lx2006
Extrinsic Cardiomyopathy
Lexeo Therapeutics
P1/2
CCC
(48)
hlx301
Neoplasm
Shanghai Henlius Biotech
P1/2
CCC
(48)
hlx301
Metastatic Neoplasm
Shanghai Henlius Biotech
P1/2
CCC
(48)
hlx43
Colon Adenocarcinoma
Shanghai Henlius Biotech
P1/2
CCC
(48)
HM06
Non-Small Cell Lung Carcinoma
Taiho Pharmaceutical Co., Ltd.
P1/2
CCC
(48)
HM06
RET Fusion Positive Cancer
Taiho Pharmaceutical Co., Ltd.
P1/2
CCC
(48)
HM15421
Fabry Disease
GC Biopharma Corp
P1/2
CCC
(48)
Hmpl-453
Neoplasm
Hutchison Medipharma Limited
P1/2
CCC
(48)
Showing 1276 to 1300 of 6,308 assets
Previous
Page 52 of 253
Next
